ASX & Press Releases

Monday, November 3, 2014

In light of the recent disappointing results of its Phase III trial of HA-Irinotecan, Alchemia Limited (ASX: ACL) today announced that it intends to withdraw resolutions from the Notice of Meeting for the company's Annual General Meeting to be held on Monday, 10 November 2014.

Tuesday, October 21, 2014

Alchemia's 2014 Annual General Meeting will be held at The Westin, 205 Collins Street, Melbourne, Victoria, Australia on the 10th of November 2014, commencing at 10:00am (Melbourne Time).

Friday, October 10, 2014

Alchemia announced today the database lock for the primary efficacy analysis of its pivotal Phase III trial of HA-Irinotecan in metastatic colorectal cancer (mCRC). The company also confirms that the trial achieved its primary endpoint analysis threshold of a minimum of 350 progression free survival (PFS) events.

Friday, October 10, 2014

Alchemia has released its Annual Report for 2014. The report can also be viewed on our website at http://www.alchemia.com.au/InvestorCentre/AnnualReports.aspx

Friday, September 12, 2014

Alchemia Ltd announced today that it is in the last stage of finalising the database for the pivotal Phase III trial of HA-Irinotecan in metastatic colorectal cancer (mCRC) and it expects to report top-line results in October 2014.

Friday, August 29, 2014

Alchemia today announced its results for the financial year 2014 with new high-calibre appointments to the board and management, and substantial progress achieved across all its drug platforms during the year.

Thursday, August 28, 2014

Alchemia announced a reported profit share of A$2.15m (US$2.02m) on sales of its generic anti-coagulant drug fondaparinux for the quarter ending 30 June 2014.

Monday, August 25, 2014

Alchemia announced today the appointment of Ms. Jenni Pilcher as its Chief Financial Officer (CFO). Ms. Pilcher brings extensive financial leadership experience to Alchemia.

Friday, August 1, 2014

Alchemia has held an investor briefing over lunch in Melbourne. The slides are presented herein, with presentations by Thomas Liquard, Peter Gibbs MD and Dr Tracey Brown.

Thursday, June 19, 2014

Alchemia announced that the first patient has been enrolled into the new clinical trial of HA-Irinotecan and Erbitux® (cetuximab); the CHIME trial. This clinical trial is being conducted as an Investigator-Sponsored trial and is jointly supported by Alchemia and Merck Serono SA (Merck Serono).

Pages